Table 2 Characteristics of infected patients according to the type of malignancy
From: Characteristics and outcomes of cancer patients in European ICUs
| Â | No cancer (n = 960) | Solid tumours (n = 168) | Haematological cancer (n = 49) |
|---|---|---|---|
Criteria for infection | Â | Â | Â |
   Clinically suspected | 750 (78.1%) | 136 (81%) | 38 (77.6%) |
   Microbiologically confirmed | 666 (69.4%) | 114 (67.9%) | 34 (69.5%) |
   Clinical signs and micro-organism | 383 (39.9%) | 71 (42.5%) | 14 (28.6%) |
Source of infection | Â | Â | Â |
   Respiratory | 648 (67.5%) | 108 (64.3%) | 38 (77.6%) |
   Abdominal | 200 (20.8%) | 56 (33.3%)$ | 7 (14.3%) |
   Blood stream | 196 (20.4%) | 26 (15.5%) | 16 (32.7)* |
   Skin | 132 (13.8%) | 23 (13.7%) | 3 (6.1%) |
   Urinary | 133 (13.9%) | 22 (13.1%) | 4 (8.2%) |
   Catheter | 87 (9.1%) | 18 (10.7%) | 6 (12.2%) |
   Cerebrospinal fluid | 15 (1.6%) | 0 (0.0%) | 0 (0.0%) |
   Unknown | 53 (5.5%) | 7 (4.1%) | 3 (6.1%) |
Gram-positive bacteria | Â | Â | Â |
   Streptococcus group D | 97 (10.1%) | 21 (12.5%) | 5 (10.2%) |
   Streptococcus pneumoniae | 42 (4.3%) | 3 (1.7%) | 1 (2.0%) |
   MRSA | 131 (13.6%) | 28 (16.6%) | 5 (10.2%) |
   Other cocci | 20 (2.1%) | 3 (1.8%) | 0 |
Gram-negative bacteria | Â | Â | Â |
   Pseudomonas | 132 (13.7%) | 21 (12.5%) | 10 (20.4%) |
   Escherichia coli | 114 (11.8%) | 34 (20.2%)$ | 10 (20.4%)* |
   Enterobacter | 53 (5.5%) | 13 (7.7%) | 1 (2.0%) |
   Klebsiella | 60 (6.2%) | 11 (6.5%) | 0 |
   Proteus | 39 (4.0%) | 9 (5.3%) | 1 (2.0%) |
   Acinetobacter | 37 (3.8%) | 3 (1.7%) | 2 (4.0%) |
   Haemophilus | 33 (2.4%) | 3 (1.8%) | 1 (2.0%) |
Fungi | Â | Â | Â |
   Candida albicans | 125 (13%) | 28 (16.7%) | 3 (6.1%) |
   Candida non-albicans | 37 (3.9%) | 9 (5.4%) | 3 (6.1%) |
   Other fungi | 13 (1.3%) | 3 (1.7%) | 1 (2.0%) |